OncoTrack

Methods for systematic next generation oncology biomarker development

groups: IMI Projects

tags: IMI Translational Medicine

First Name
David
Last Name
Henderson
Affiliation
Bayer AG
Email
david.henderson@bayer.com
Business Phone Number
00493040008769
Business Fax Number
-
Business Address
Bayer AG, R&D Policy & Networking, 13342 Berlin, Germany
Project Website
http://www.oncotrack.eu
Version
V1.0
Date of creation of the dataset
2017-01-05
Date of the last update of the dataset
2017-01-05
Funding
IMI
Reference Publications
-
Data Standards Implemented
CDISC
Therapeutic Area Standards (Disease Area)
-
Study Protocal Description
OncoTrack attempts to address the core problems of drug-based cancer therapies: the low response rate of patients to their therapies, as well as its inevitable consequence, the low approval rates of oncology drugs. Only about 10% of cancer drug candidates entering clinical development are granted marketing authorization. Our program is based on two seminal developments: significant progress in our ability to analyze the molecular characteristics of individual tumors and patients (predominantly, but not exclusively, due to advancements in DNA sequencing techniques) and through the development of sophisticated computational models, which can convert this abundance of data into predictions. To address this challenge, the OncoTrack consortium recruited over 300 colon cancer patients (stages I-IV) and developed a pre-clinical platform generating a compendium of drug sensitivity data totalling > 4,000 assays testing 16 clinical drugs on patient-derived in vivo and in vitro models. This large biobank of tumors, organoid culturess and xenografts, with extensive omics data comparing donor tumors and derived models, provides a resource for advancing our understanding of colon cancer.
Multi-center Study
True
Description of Cohorts
(1) Patients with primary diagnosis of colon cancer (2) Patients with metastatic colon cancer (3) Validation cohort of patients receiving therapy with 5FU
Study Type
Observational; Xenografts; 3D cell cultures
Study Type Comment
-
Primary Purpose
Biomarker discovery and validation
Study Phase
N/A - not a clinical trial
Intervention Model
N/A
Study Classification
N/A
Indication
Carcinoma of the colon
Age Range (Low Limit) of Study
18
Age Range (Upper Limit) of Study
93
Age Unit (of the above ranges)
Year
BMI Range
N/A
BMI Range (lower limit)
-
BMI Range (upper limit)
-
Informed Consent
True
Planned Arm (Description of Sub-cohorts)
-
Name of Treatment
Drugs tested: Oxaliplatin, Irinotecan, 5-FU, Cetuximab, AZD8931, AZD6244, Afatinib, Avastin, Regorafenib, Nintedanib, mTOR FR, BI836842 (IGF1/2 mAb), AZ1 (Tank-I), Volitinib
Standardized Name of Treatment
N/A
Category
Antineoplastics
Dose Description
Various
Organism
Homo sapiens
Body System or Organ Class
Colon cancer
Total Number of (Human) Subjects
322
Total Number of (Non-Human) Subjects
322
Number of Subjects in Each Cohorts (if multi-cohorts)
(1) 261 primary tumor (2) 61 metastatic tumor
Detail Subject Composition
No control cohort
Type of Samples Collected
Blood Serum Plasma Tumor Tissue Healthy Surrounding Tissue (near tumor)
Number of Samples Collected
>6000
Samples Details
-
Secondary Analysis
Whole genome sequencing, Exome sequencing, Transcriptome array, Methylation array, MicroRNA array, RNASeq, Proteomics, Deep-Sequencing